RxDoctor Payments Data

Susan Gagnon

Psychiatric/Mental Health · Lincoln, RINPI 1922280817

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 77 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AbbVie accounts for 88.2% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2022 at $805 and has fallen 94.1% since, to $47 in 2025.

$1,430in general payments, 2019–2025

Across 77 payments — averaging $18.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Axsome Therapeutics, Inc.$103
  • Supernus Pharmaceuticals, Inc.$25
  • Corium, LLC$21
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$19

What the payments were for

  • Food & beverage$1,430100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,430 in reported general payments places this provider in the 70th percentile of 196 psychiatric/mental health providers in Rhode Island.

See all psychiatric/mental health providers in Rhode Island

Medicare billing

Part B allowed, 2024
$26,157
Medicare patients
52
Services billed
261

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate15$116,250
Wellbutrin XlBupropion Hcl13$24,618
VraylarCariprazine Hcl11$18,522
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine154$5,643
Duloxetine Hcl122$4,990
Lurasidone Hcl17$4,979
Aripiprazole41$4,619
Clonazepam457$4,113
Armodafinil49$3,980
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine66$3,964
Bupropion XlBupropion Hcl101$2,927
Quetiapine Fumarate98$2,869
Methylphenidate Hcl126$2,561
Venlafaxine Hcl ErVenlafaxine Hcl64$1,802
Methylphenidate ErMethylphenidate Hcl22$1,551

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$1,261$18,52211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 196 psychiatric/mental health providers in Rhode Island.

Other psychiatric/mental health in Lincoln

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →